PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
32721103-0	2018	Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.	Imatinib Mesylate	84-92	homeobox A4	Homo sapiens	28-33
32721103-5	2018	AIM: To investigate the correlation of HOXA4 and HOXA5 promoter DNA hypermethylation with imatinib resistance among CML patients.	Imatinib Mesylate	90-98	homeobox A4	Homo sapiens	39-44
32721103-10	2018	Chronic myeloid leukemia patients with >=63% HOXA4 and HOXA5 methylation level were shown to have 3.78 and 3.95 times the odds, respectively, to acquire resistance to imatinib.	Imatinib Mesylate	167-175	homeobox A4	Homo sapiens	45-50
32721103-12	2018	CONCLUSION: Hypermethylation of the HOXA4 and HOXA5 promoter is correlated with imatinib resistance and with further investigation, it could be a potential epigenetic biomarker in supplement to the BCR-ABL gene mutation in predicting imatinib treatment response among CML patients but could not be considered as a prognostic marker.	Imatinib Mesylate	80-88	homeobox A4	Homo sapiens	36-41
32721103-12	2018	CONCLUSION: Hypermethylation of the HOXA4 and HOXA5 promoter is correlated with imatinib resistance and with further investigation, it could be a potential epigenetic biomarker in supplement to the BCR-ABL gene mutation in predicting imatinib treatment response among CML patients but could not be considered as a prognostic marker.	Imatinib Mesylate	234-242	homeobox A4	Homo sapiens	36-41
30501603-0	2018	HOXA4-Dependent Transcriptional Activation of AXL Promotes Cisplatin- Resistance in Lung Adenocarcinoma Cells.	Cisplatin	59-68	homeobox A4	Homo sapiens	0-5
23484077-0	2013	HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients.	Imatinib Mesylate	88-105	homeobox A4	Homo sapiens	0-5
9272954-4	1997	We have extended the transgenic analysis to Hoxa4 identifying mesodermal, neural and retinoid responsive components in the 3" flanking region of that gene, which reflect aspects of endogenous Hoxa4 expression.	Retinoids	85-93	homeobox A4	Homo sapiens	44-49
9272954-4	1997	We have extended the transgenic analysis to Hoxa4 identifying mesodermal, neural and retinoid responsive components in the 3" flanking region of that gene, which reflect aspects of endogenous Hoxa4 expression.	Retinoids	85-93	homeobox A4	Homo sapiens	192-197
9272954-5	1997	Comparative analysis of the retinoid responses of Hoxd4, Hoxa4 and Hoxb4 reveals that, while they can be rapidly induced by RA, there is a window of competence for this response, which is different to that of more 3" Hox genes.	Retinoids	28-36	homeobox A4	Homo sapiens	57-62
9272954-5	1997	Comparative analysis of the retinoid responses of Hoxd4, Hoxa4 and Hoxb4 reveals that, while they can be rapidly induced by RA, there is a window of competence for this response, which is different to that of more 3" Hox genes.	Tretinoin	124-126	homeobox A4	Homo sapiens	57-62
33082556-9	2021	Re-expression of HOXA4 in cell lines and primary CLL cells significantly increased apoptosis in response to treatment with fludarabine, ibrutinib and idelalisib.	fludarabine	123-134	homeobox A4	Homo sapiens	17-22
33082556-9	2021	Re-expression of HOXA4 in cell lines and primary CLL cells significantly increased apoptosis in response to treatment with fludarabine, ibrutinib and idelalisib.	ibrutinib	136-145	homeobox A4	Homo sapiens	17-22
33082556-9	2021	Re-expression of HOXA4 in cell lines and primary CLL cells significantly increased apoptosis in response to treatment with fludarabine, ibrutinib and idelalisib.	idelalisib	150-160	homeobox A4	Homo sapiens	17-22
30196354-0	2019	HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.	mir-138	16-23	homeobox A4	Homo sapiens	0-5
30196354-0	2019	HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.	Gefitinib	53-62	homeobox A4	Homo sapiens	0-5
30196354-10	2019	MiR-138 was directly regulated by Homeobox A4 (HOXA4) via an HOXA4-binding site on the promoter region.	mir-138	0-7	homeobox A4	Homo sapiens	34-45
30196354-10	2019	MiR-138 was directly regulated by Homeobox A4 (HOXA4) via an HOXA4-binding site on the promoter region.	mir-138	0-7	homeobox A4	Homo sapiens	47-52
30196354-10	2019	MiR-138 was directly regulated by Homeobox A4 (HOXA4) via an HOXA4-binding site on the promoter region.	mir-138	0-7	homeobox A4	Homo sapiens	61-66
30196354-12	2019	We demonstrated that miR-138 is regulated by HOXA4 and exerts its functions via inhibiting EGFR expression in NSCLC cells.	mir-138	21-28	homeobox A4	Homo sapiens	45-50
30203578-12	2019	MCF7 cells treated with RG108 showed decreased HOXA4 and IGF1 expressions.	RG108	24-29	homeobox A4	Homo sapiens	47-52
29402501-10	2018	HOXA4 or HOXB3 overexpression in ovarian cancer cells decreased sensitivity to cisplatin and attenuated the generation of cisplatin-induced ROS (P<0.05).	Cisplatin	79-88	homeobox A4	Homo sapiens	0-5
29402501-10	2018	HOXA4 or HOXB3 overexpression in ovarian cancer cells decreased sensitivity to cisplatin and attenuated the generation of cisplatin-induced ROS (P<0.05).	Cisplatin	122-131	homeobox A4	Homo sapiens	0-5
29402501-10	2018	HOXA4 or HOXB3 overexpression in ovarian cancer cells decreased sensitivity to cisplatin and attenuated the generation of cisplatin-induced ROS (P<0.05).	Reactive Oxygen Species	140-143	homeobox A4	Homo sapiens	0-5
28877686-11	2017	Our analyses of primary AML cells during in vivo treatment suggest that ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3), but altered function of DNA methyl transferase 3A (DNMT3A) and G-protein coupled receptor signaling may also contribute to the effect of the overall treatment.	Tretinoin	72-76	homeobox A4	Homo sapiens	137-142
19144990-6	2009	Knockdown of HOTAIRM1 quantitatively blunted RA-induced expression of HOXA1 and HOXA4 during the myeloid differentiation of NB4 cells, and selectively attenuated induction of transcripts for the myeloid differentiation genes CD11b and CD18, but did not noticeably impact the more distal HOXA genes.	Tretinoin	45-47	homeobox A4	Homo sapiens	80-85
19281776-8	2009	However, HOXA4 downregulation enhanced EGFR phosphorylation and migration in serum-starved OSE and ovarian cancer cells in response to EGF, and enhanced migration of all ovarian cancer lines in 5% serum even without EGF treatment.	serine O-sulfate	91-94	homeobox A4	Homo sapiens	9-14